AMICUS THERAPEUTICS INC's ticker is FOLD and the CUSIP is 03152W109. A total of 249 filers reported holding AMICUS THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is 0.28 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,098,126 | -6.2% | 419,254 | -3.2% | 0.00% | 0.0% |
| Q2 2023 | $5,437,299 | +7.0% | 432,906 | -5.6% | 0.00% | 0.0% |
| Q1 2023 | $5,083,300 | +24.1% | 458,368 | +36.6% | 0.00% | +100.0% |
| Q4 2022 | $4,095,000 | +14.6% | 335,464 | -1.9% | 0.00% | 0.0% |
| Q3 2022 | $3,572,000 | -19.4% | 342,084 | -17.2% | 0.00% | -50.0% |
| Q2 2022 | $4,433,000 | +39.8% | 412,963 | +23.4% | 0.00% | +100.0% |
| Q1 2022 | $3,170,000 | -11.6% | 334,774 | +7.8% | 0.00% | 0.0% |
| Q4 2021 | $3,588,000 | +46.1% | 310,507 | +20.7% | 0.00% | 0.0% |
| Q3 2021 | $2,456,000 | +24.2% | 257,215 | +25.5% | 0.00% | 0.0% |
| Q2 2021 | $1,977,000 | -18.1% | 204,978 | -16.1% | 0.00% | 0.0% |
| Q1 2021 | $2,414,000 | -59.1% | 244,341 | -4.5% | 0.00% | -50.0% |
| Q4 2020 | $5,909,000 | +99.9% | 255,910 | +22.2% | 0.00% | +100.0% |
| Q3 2020 | $2,956,000 | -29.2% | 209,347 | -24.4% | 0.00% | -50.0% |
| Q2 2020 | $4,174,000 | +22.6% | 276,841 | -24.9% | 0.00% | 0.0% |
| Q1 2020 | $3,404,000 | +65.9% | 368,411 | +74.9% | 0.00% | +100.0% |
| Q4 2019 | $2,052,000 | -75.3% | 210,685 | -79.6% | 0.00% | -75.0% |
| Q3 2019 | $8,302,000 | -32.8% | 1,035,046 | +4.6% | 0.00% | -33.3% |
| Q2 2019 | $12,353,000 | -7.3% | 989,777 | +1.0% | 0.01% | 0.0% |
| Q1 2019 | $13,331,000 | +43.3% | 980,202 | +0.9% | 0.01% | +20.0% |
| Q4 2018 | $9,305,000 | -70.5% | 971,251 | -62.8% | 0.01% | -54.5% |
| Q3 2018 | $31,527,000 | -22.4% | 2,607,748 | +0.3% | 0.01% | -38.9% |
| Q2 2018 | $40,604,000 | +30.1% | 2,599,514 | +25.3% | 0.02% | +28.6% |
| Q1 2018 | $31,201,000 | +41501.3% | 2,074,535 | +20575.1% | 0.01% | – |
| Q3 2016 | $75,000 | +13.6% | 10,034 | -17.0% | 0.00% | – |
| Q2 2016 | $66,000 | -41.6% | 12,092 | -9.4% | 0.00% | – |
| Q1 2016 | $113,000 | -4.2% | 13,348 | +9.7% | 0.00% | – |
| Q4 2015 | $118,000 | -93.7% | 12,169 | -90.9% | 0.00% | -100.0% |
| Q3 2015 | $1,866,000 | -33.9% | 133,394 | -32.8% | 0.00% | -50.0% |
| Q2 2015 | $2,824,000 | +37.6% | 198,524 | +5.3% | 0.00% | +100.0% |
| Q1 2015 | $2,052,000 | +4.5% | 188,565 | -20.1% | 0.00% | 0.0% |
| Q4 2014 | $1,964,000 | +45.6% | 236,039 | +4.1% | 0.00% | 0.0% |
| Q3 2014 | $1,349,000 | +33625.0% | 226,803 | +11868.5% | 0.00% | – |
| Q3 2013 | $4,000 | 0.0% | 1,895 | -0.5% | 0.00% | – |
| Q2 2013 | $4,000 | – | 1,905 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 10,524,022 | $127,972,108 | 12.11% |
| Perceptive Advisors | 27,692,917 | $336,745,870 | 11.23% |
| Redmile Group, LLC | 16,944,621 | $206,046,591 | 9.80% |
| Finepoint Capital LP | 1,489,025 | $18,106,544 | 9.02% |
| CM Management, LLC | 450,000 | $5,472,000 | 5.81% |
| Avoro Capital Advisors LLC | 27,400,000 | $333,184,000 | 5.20% |
| MPM BioImpact LLC | 716,139 | $8,708,250 | 2.32% |
| Artal Group S.A. | 4,062,567 | $49,401 | 2.12% |
| SECTORAL ASSET MANAGEMENT INC | 803,464 | $9,770,122 | 1.90% |
| GREAT POINT PARTNERS LLC | 857,000 | $10,421,120 | 1.90% |